LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/K2M Turns 10 – Biggest Private Spine Company
Company News

K2M Turns 10 – Biggest Private Spine Company

January 28, 2014 2 min read Premium comments

Advertisement

K2M Turns 10 – Biggest Private Spine Company
Source: Wikimedia
Secondary

John Kostuik, M.D.’s baby is 10 years old and has grown up to become the largest private spinal implant company in the world.

K2M Group Holdings, Inc. (K2M) turned 10 years old on January 24, 2014. Before co-founding K2M, Dr. Kostuik was the chief of spine surgery at The Johns Hopkins University School of Medicine. He also served as president of the Scoliosis Research Society and the North American Spine Society of which he was an original member/organizer.

A statement from the company said its rapid development of over 57 spinal technologies and related techniques is a result of the unique approach to innovation. “Dr. Kostuik, champion of [the company’s] patient focused culture, has always believed in the importance of valuing the voice of the surgeon. With that in mind, the company’s integrated product development strategy has focused on incorporating the input of a global cross section of key opinion leader surgeons. The collaboration between K2M engineers, researchers, product managers, clinical specialists and industry experts working closely with these leading scientific advisors has led to a broad portfolio of products.”

“What started in January of 2004 as a vision to be a leader in spine is today a global family of over 750 professionals. Since its inception, it has focused on innovating leading technologies for surgeons treating the most complex spinal conditions. In so doing, K2M has helped touch the lives of tens of thousands of patients around the world, ” said company President and CEO Eric Major.

The company provides technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients. K2M’s product development pipeline includes: spinal stabilization systems, minimally invasive systems, biologics, and other advancing technologies, such as motion preservation, annular repair, and nucleus replacement.

Platform Technologies

The company’s platform technologies include:

  • MESA Technology. “A top-loading and low-profile spinal system featuring Zero-Torque Technology and 60° range of motion, while providing the surgeon the ability to one-step lock without torsional stress applied to the spine.”
  • RANGE Complex Spine Technology represents the complete product portfolio K2M has to offer in the specialized area of the complex spine.
  • tifix Locking Technology allows for the “flexibility to insert screws at various angles and lock them to the plate. It’s a one-step locking mechanism—no secondary locking feature necessary. Capable of repeated screw adjustment without compromising the locking mechanism. No bend zones required for precise plate contouring.”
  • RAIL 4D Technology offers “a “beam-like” design providing enhanced rigidity and strength to aid in the restoration of sagittal balance, while maintaining a low-profile.”

Happy birthday, K2M.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy